We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-10.00 | -0.52% | 1,925.00 | 1,925.00 | 1,927.00 | 1,942.00 | 1,924.00 | 1,938.00 | 300,009 | 16:29:58 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 22.16 | 4.26B |
TIDMHIK
RNS Number : 3636S
Hikma Pharmaceuticals Plc
20 December 2016
Notification and public disclosure of transactions by persons discharging managerial responsibilities
The attached individual notification made under article 19.1 of the Market Abuse Regulation ("MAR") relates to the purchase by Darhold Limited of Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Chairman and Chief Executive, Vice Chairman and a Non-executive Director are directors of and shareholders in Darhold Limited. This announcement is made in accordance with article 19.3 of MAR.
Said Darwazah
1 Details of the person discharging managerial responsibilities / person closely associated --- ------------------------------------------------------------ a) Name Said Darwazah --- --------------------- ------------------------------------- 2 Reason for the notification --- ------------------------------------------------------------ a) Position/status Chairman and Chief Executive Officer / PDMR --- --------------------- ------------------------------------- b) Initial notification Initial notification /Amendment --- --------------------- ------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --- ------------------------------------------------------------ a) Name Hikma Pharmaceuticals PLC --- --------------------- ------------------------------------- b) LEI 549300BNS685UXH4JI75 --- --------------------- ------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- ------------------------------------------------------------ a) Description Description: Ordinary shares of 10 of the financial pence each instrument, ID Code: GB00B0LCW083 type of instrument and identification code --- --------------------- ------------------------------------- b) Nature of Acquisition by Darhold Limited of the transaction 140,730 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Chairman and Chief Executive is a director of and shareholder in Darhold Limited with an equity interest of 21.67%. --- --------------------- ------------------------------------- c) Price(s) and Price(s): GBP18.49 volume(s) Volume(s): 90,730 Price(s): GBP17.90 Volume(s): 50,000 --- --------------------- ------------------------------------- d) Aggregated Aggregated volume: 140,730 information Price: GBP18.27 --- --------------------- ------------------------------------- e) Date of the 16 and 19 December 2016 transaction --- --------------------- ------------------------------------- f) Place of the London Stock Exchange (XLON) transaction --- --------------------- -------------------------------------
Mazen Darwazah
1 Details of the person discharging managerial responsibilities / person closely associated --- --------------------------------------------------------------- a) Name Mazen Darwazah --- --------------------- ---------------------------------------- 2 Reason for the notification --- --------------------------------------------------------------- a) Position/status Executive Vice Chairman / PDMR --- --------------------- ---------------------------------------- b) Initial notification Initial notification /Amendment --- --------------------- ---------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --- --------------------------------------------------------------- a) Name Hikma Pharmaceuticals PLC --- --------------------- ---------------------------------------- b) LEI 549300BNS685UXH4JI75 --- --------------------- ---------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- --------------------------------------------------------------- a) Description Description: Ordinary shares of 10 of the financial pence each instrument, ID Code: GB00B0LCW083 type of instrument and identification code --- --------------------- ---------------------------------------- b) Nature of Acquisition by Darhold Limited of the transaction 140,730 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Executive Vice Chairman is a director of and shareholder in Darhold Limited with an equity interest of 10.92%. --- --------------------- ---------------------------------------- c) Price(s) and Price(s): GBP18.49 volume(s) Volume(s): 90,730 Price(s): GBP17.90 Volume(s): 50,000 --- --------------------- ---------------------------------------- d) Aggregated Aggregated volume: 140,730 information Price: GBP18.27 --- --------------------- ---------------------------------------- e) Date of the 16 and 19 December 2016 transaction --- --------------------- ---------------------------------------- f) Place of the London Stock Exchange (XLON) transaction --- --------------------- ----------------------------------------
Mohammed 'Ali' Al-Husry
1 Details of the person discharging managerial responsibilities / person closely associated --- ----------------------------------------------------------------- a) Name Mohammed 'Ali' Al-Husry --- --------------------- ------------------------------------------ 2 Reason for the notification --- ----------------------------------------------------------------- a) Position/status Non-executive Director/ PDMR --- --------------------- ------------------------------------------ b) Initial notification Initial notification /Amendment --- --------------------- ------------------------------------------ 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --- ----------------------------------------------------------------- a) Name Hikma Pharmaceuticals PLC --- --------------------- ------------------------------------------ b) LEI 549300BNS685UXH4JI75 --- --------------------- ------------------------------------------ 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- ----------------------------------------------------------------- a) Description Description: Ordinary shares of 10 of the financial pence each instrument, ID Code: GB00B0LCW083 type of instrument and identification code --- --------------------- ------------------------------------------ b) Nature of Acquisition by Darhold Limited of the transaction 140,730 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Non-Executive Director is a director of and shareholder in Darhold Limited with an equity interest of 8.01% through DKYB Limited, a vehicle owned by his family. --- --------------------- ------------------------------------------ c) Price(s) and Price(s): GBP18.49 volume(s) Volume(s): 90,730 Price(s): GBP17.90 Volume(s): 50,000 --- --------------------- ------------------------------------------ d) Aggregated Aggregated volume: 140,730 information Price: GBP18.27 --- --------------------- ------------------------------------------ e) Date of the 16 and 19 December 2016 transaction --- --------------------- ------------------------------------------ f) Place of the London Stock Exchange (XLON) transaction --- --------------------- ------------------------------------------
Peter Speirs, Company Secretary, Responsible for releasing this announcement
20 December 2016
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBGBDDLSDBGLG
(END) Dow Jones Newswires
December 20, 2016 05:47 ET (10:47 GMT)
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions